In last trading session, Dyne Therapeutics Inc (NASDAQ:DYN) saw 1.28 million shares changing hands with its beta currently measuring 1.08. Company’s recent per share price level of $13.54 trading at $0.08 or 0.59% at ring of the bell on the day assigns it a market valuation of $1.38B. That closing price of DYN’s stock is at a discount of -250.44% from its 52-week high price of $47.45 and is indicating a premium of 2.29% from its 52-week low price of $13.23. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.62 million shares which gives us an average trading volume of 1.60 million if we extend that period to 3-months.
For Dyne Therapeutics Inc (DYN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.91 in the current quarter.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Upright in the green during last session for gaining 0.59%, in the last five days DYN remained trading in the red while hitting it’s week-highest on Friday, 01/24/25 when the stock touched $13.54 price level, adding 6.69% to its value on the day. Dyne Therapeutics Inc’s shares saw a change of -42.53% in year-to-date performance and have moved -4.04% in past 5-day. Dyne Therapeutics Inc (NASDAQ:DYN) showed a performance of -44.67% in past 30-days. Number of shares sold short was 9.4 million shares which calculate 5.56 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 52.5 to the stock, which implies a rise of 74.21% to its current value. Analysts have been projecting 52 as a low price target for the stock while placing it at a high target of 53. It follows that stock’s current price would drop -284.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -284.05% for stock’s current value.
Dyne Therapeutics Inc (DYN) estimates and forecasts
Statistics highlight that Dyne Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -68.39% of value to its shares in past 6 months, showing an annual growth rate of 12.91% while that of industry is 17.30. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -106.26% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 12.26% while estimates for its earnings growth in next 5 years are of 1.02%.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
Insiders are in possession of 0.77% of company’s total shares while institution are holding 112.25 percent of that, with stock having share float percentage of 113.13%. Investors also watch the number of corporate investors in a company very closely, which is 112.25% institutions for Dyne Therapeutics Inc that are currently holding shares of the company. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the top institutional holder at DYN for having 8.02 million shares of worth $283.03 million. And as of 2024-06-30, it was holding 9.8961 of the company’s outstanding shares.
The second largest institutional holder is FCPM III SERVICES B.V., which was holding about 7.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6804 of outstanding shares, having a total worth of $276.86 million.
